Alphavirus RNA Replicon Reprogramming Without Genomic Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming somatic cells to achieve pluripotency face challenges such as the use of viral vectors that can cause genomic integration and oncogenic risks, ethical concerns with embryonic stem cells, and inefficiencies in producing high-quality de-differentiated cells.
Innovation Solution
The use of RNA replicons derived from alphaviruses, specifically designed to encode reprogramming factors like OCT4, SOX2, KLF4, c-MYC, LIN28, and NANOG, without overlapping with non-structural protein coding sequences, allowing for efficient reprogramming of somatic cells to stem-like cells without genomic modification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used to deliver reprogramming factors, then reprogramming efficiency is improved, but genomic integration and oncogenic risks increase
Solution Approach 1:
The patent extracts the reprogramming function from viral vectors by using RNA replicons that replicate independently in the cytoplasm without integrating into the host genome. The RNA replicon system separates the delivery mechanism (RNA replication) from the reprogramming function (transcription factor expression), eliminating genomic integration risks while maintaining high expression levels of reprogramming factors
Solution Approach 2:
The patent introduces RNA replicons as an intermediary between DNA and protein expression. The RNA replicon acts as a self-amplifying mRNA that temporarily expresses reprogramming factors without permanent genomic modification, serving as a safe bridge that provides high expression levels without the risks of viral integration
2Adaptability or versatility
If embryonic stem cells are used for cell therapy, then pluripotency is achieved, but ethical concerns and immunogenicity increase
Solution Approach 1:
The patent inverts the traditional approach by instead of using embryonic stem cells and attempting to differentiate them, it takes differentiated somatic cells and reprograms them back to a pluripotent state using RNA replicons. This reversal avoids all ethical issues associated with embryonic stem cells while achieving the same therapeutic pluripotent cell goal
Solution Approach 2:
The patent creates a copy of the pluripotent state in somatic cells through reprogramming, rather than using actual embryonic stem cells. The RNA replicons deliver transcription factors that recreate the pluripotent gene expression profile in somatic cells, providing an ethical alternative that is functionally equivalent
3Reliability
If adult stem cells are used for transplantation, then immunological privilege is maintained, but differentiation potential and growth capacity are limited
Solution Approach 1:
The patent makes the differentiation potential dynamic by using RNA replicons to temporarily upregulate pluripotency transcription factors in adult stem cells. This dynamic adjustment allows the cells to expand and differentiate more extensively during culture, while the cells remain genetically identical to the patient, preserving immunological privilege upon transplantation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables high-quality reprogramming of somatic cells to stem-like cells, facilitating autologous cell transplantation and reducing the risk of genomic integration and oncogenic effects, while providing a scalable and cost-effective method for cell therapy applications.
Implementation Method 1
an RNA replicon that can be replicated by a replicase of alphavirus origin
Implementation Method 2
methods for de-differentiating somatic cells into cells having stem cell characteristics, in particular pluripotency
Data Source
Figure 1A~1C
Figure 2A~2D
Figure 3A~3C
AI summary
The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a reprogramming factor. Such RNA replicons are useful for expressing a reprogramming factor in a cell, in particular a somatic cell. Cells engineered to express such reprogramming factors are useful in cell transplantation therapies.